[1]CurrentPatentAssignee:PFIZERINC-WO2013/142875,2013,A1Locationinpatent:Paragraph00154
[1]CurrentPatentAssignee:PFIZERINC-WO2013/142875,2013,A1Locationinpatent:Paragraph00153
[2]CurrentPatentAssignee:PFIZERINC-US9457093,2016,B2Locationinpatent:Page/Pagecolumn21;22
[3]DeVries,Peter;Forero-Torres,Andres;Kulukian,Anita;Lee,Patrice;Peterson,Scott;Rosler,Robert;Taylor,Janelle;Watson,Daniel[MolecularCancerTherapeutics,2020,vol.19,#4,p.976-987]
[4]Lyu,Yaodong;Huang,Liliang;Zhu,Xiaolei;Lu,Sheng;Mao,Yongjun[OrganicPreparationsandProceduresInternational,2021,vol.53,#6,p.554-561]
[5]CurrentPatentAssignee:PFIZERINC-WO2013/56108,2013,A2Locationinpatent:Paragraph000141
[6]Müller,Marius;Shalgunov,Vladimir;Hvass,Lars;Jørgensen,JesperT.;Kramer,Vasko;Staudt,Markus;Battisti,UmbertoMaria;Kjaer,Andreas;Herth,MatthiasM.[BioorganicandMedicinalChemistryLetters,2023,vol.80]
[7]Müller,Marius;Shalgunov,Vladimir;Hvass,Lars;Jørgensen,JesperT.;Kramer,Vasko;Staudt,Markus;Battisti,UmbertoMaria;Kjaer,Andreas;Herth,MatthiasM.[BioorganicandMedicinalChemistryLetters,2023,vol.80]
[8]CurrentPatentAssignee:GUANGDONGRUNXINGBIOLOGICALTECH-CN115650977,2023,ALocationinpatent:Paragraph0044-0047
[1]CurrentPatentAssignee:SHANGHAIUNIVERSITYOFENGINEERINGSCIENCES-CN109942576,2019,A
[2]Bu,Lehao;Chen,Wenxin;Liu,Yaowei;Mao,Yongjun;Yin,Lingfeng;Zhang,Long[Synthesis,2019,vol.51,#13,p.2660-2664]
[3]Bu,Lehao;Chen,Wenxin;Liu,Yaowei;Mao,Yongjun;Yin,Lingfeng;Zhang,Long[Synthesis,2019,vol.51,#13,p.2660-2664]
[4]CurrentPatentAssignee:WUHANNINEZHOULUSTUMEDICINESCIENCEANDTECHLIMITEDCOMPANY-CN114230568,2022,A
[1]Patent:CN109942576,2019,A
[1]CurrentPatentAssignee:SHANGHAIUNIVERSITYOFENGINEERINGSCIENCES-CN109942576,2019,A
[2]Bu,Lehao;Chen,Wenxin;Liu,Yaowei;Mao,Yongjun;Yin,Lingfeng;Zhang,Long[Synthesis,2019,vol.51,#13,p.2660-2664]
[3]Bu,Lehao;Chen,Wenxin;Liu,Yaowei;Mao,Yongjun;Yin,Lingfeng;Zhang,Long[Synthesis,2019,vol.51,#13,p.2660-2664]
Title: Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2(+)-Advanced Solid Tumors, with an Expansion Cohort in HER2(+) Metastatic Breast Cancer (MBC).
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20170715
Title: Moulder-Thompson S, et al. Phase 1 Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+ Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC). Clin Cancer Res. 2017 Jan 4. pii: clincanres.1496.2016.
Title: Abstract: In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 852. doi:1538-7445.AM2012-852
Title: P. Lee, et al. In Vivo Activity of ARRY-380, a Potent, Small Molecule Inhibitor of ErbB2 in Combination with RP-56976. Cancer Research
